COVID-19 and Cold Agglutinin Hemolytic Anemia

Area of Science:

• Internal Medicine
• Hematology
• Infectious Diseases

Background:

• COVID-19 is a global pandemic characterized by respiratory symptoms and a significant inflammatory response.
• A hypercoagulable state is frequently observed in COVID-19 patients, leading to thrombotic complications.
• The interplay between COVID-19, thrombosis, and autoimmune conditions requires further investigation.

Observation:

• A patient presented with symptoms of cerebrovascular accident and confirmed blood clots in both upper extremities.
• Laboratory tests revealed the presence of cold agglutinin autoimmune hemolytic anemia (AIHA).
• The patient's condition rapidly deteriorated, resulting in death within 48 hours of admission.

Findings:

• This case describes a rare occurrence of cold agglutinin AIHA in a patient with COVID-19.
• The association between COVID-19, AIHA, and severe thrombotic events is not well-established.
• The patient experienced multiple thrombotic events, including stroke and peripheral clots.

Implications:

• This case underscores the importance of considering AIHA in the differential diagnosis of thrombotic events in COVID-19 patients.
• Early diagnosis and appropriate management of AIHA may be crucial for improving outcomes in these patients.
• Further research is needed to elucidate the mechanisms linking COVID-19, AIHA, and thrombosis and to guide therapeutic strategies.